Results 61 to 70 of about 10,239 (207)

A case of Lomentospora prolificans endophthalmitis treated with the novel antifungal agent Olorofim

open access: yesJournal of Ophthalmic Inflammation and Infection
Abstract Purpose To report a case of endogenous Lomentospora prolificans endophthalmitis treated with the novel antifungal agent Olorofim. Case report A 57-year-old man developed disseminated Lomentospora prolificans with right endophthalmitis on the background of ...
Michael Dong   +3 more
openaire   +3 more sources

Innovative Drug Delivery Systems for the Treatment of Glaucoma

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 2, June 2026.
This review aims to provide a comprehensive overview of current topical drug delivery strategies for ocular hypotensive agents in glaucoma therapy. Additionally, it discusses the potential impact of emerging nanotechnological and biomaterial‐based systems in shaping the future of ophthalmic drug delivery, with an emphasis on enhancing efficacy, safety,
Jing Chu   +9 more
wiley   +1 more source

Smart Polymer‐Based Drug Delivery Systems for Managing Infective Conjunctivitis: Advances and Future Prospects

open access: yesNano Select, Volume 7, Issue 6, June 2026.
The introduction covers the background and significance of conjunctivitis. It continues with a review of etiology, epidemiology, and clinical manifestations. Diagnostic methods are described, followed by discussions on pathophysiology and classification. Current treatment strategies, preventive measures, and therapeutic challenges are analyzed.
Xia Linkang   +11 more
wiley   +1 more source

In Vitro and In Vivo Evaluation of Three Newly Isolated Bacteriophage Candidates, phiEF7H, phiEF14H1, phiEF19G, for Treatment of Enterococcus faecalis Endophthalmitis

open access: yes, 2021
Post-operative endophthalmitis caused by Enterococcus spp. progresses rapidly and often results in substantial and irreversible vision loss. Therefore, novel alternative treatments that are effective against enterococcal endophthalmitis are required ...
Takako Ujihara   +11 more
core   +1 more source

Clinicomicrobiological profile of endophthalmitis: A 10 year experience in a Tertiary Care Center in North India

open access: yesIndian Journal of Pathology and Microbiology, 2017
Purpose: To determine the clinicomicrobiological profile of infectious agents and their antibiotic susceptibility in different type of endophthalmitis. Methods: A retrospective review of clinical and microbiological records from January 2001 to December ...
Gita Satpathy   +6 more
doaj   +1 more source

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page e382-e396, June 2026.
Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper   +9 more
wiley   +1 more source

Evaluating the efficacy of pars plana vitrectomy in the management of endophthalmitis after following the endophthalmitis vitrectomy study: A systematic review and meta-analysis

open access: yesTzu Chi Medical Journal
Endophthalmitis is a devastating eye complication that requires prompt and effective treatment. A pivotal study in the field of endophthalmitis treatment is the endophthalmitis vitrectomy study (EVS), conducted over a decade ago. The primary objective of
Maria Angelia   +4 more
doaj   +1 more source

Prevalence and causes of low vision and blindness in an urban population: The Chennai Glaucoma Study

open access: yesIndian Journal of Ophthalmology, 2014
Aim: To evaluate the prevalence and causes of low vision and blindness in an urban south Indian population. Settings and Design: Population-based cross-sectional study.
Lingam Vijaya   +4 more
doaj   +1 more source

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

open access: yesActa Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem   +5 more
wiley   +1 more source

Endophthalmitis — a rare but dangerous complication of intravitreal anti-VEGF injections

open access: yes, 2023
Agents blocking vascular endothelial growth factor (anti-VEGF) — aflibercept, bevacizumab, and ranibizumab are commonly used drugs in the treatment of retinal vascular diseases, including age-related macular degeneration, diabetic retinopathy, retinal ...
Kawecka, Weronika; Students’ Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Lublin Poland   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy